GH Research PLC
GHRSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeGH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. Valued at $1.65B, GHRS is a small-cap name in its sector. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression.
Market Cap
$1.65B
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
-12.00
EPS (TTM)
$-0.91
EPS (Fwd)
$-2.00
ROE
-19.7%
ROA
-14.0%
Cash
$267.3M
Total Debt
$432,000
Free CF
-$32.7M
52W Change
107.5%
Annual Financials
Cash vs Debt
GH Research PLC holds $267.3M in cash against $432K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$32.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -19.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for GH Research PLC and its sector.